• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 5. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Acetals
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Acetals

Professional Introduction to (4R,5R)-5-Methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic Acid (CAS No. 67812-33-3)

Compound CAS No. 67812-33-3, specifically identified as (4R,5R)-5-Methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid, represents a significant molecule in the realm of chemical and pharmaceutical research. This compound has garnered considerable attention due to its unique structural features and potential applications in drug development and synthetic chemistry. The stereochemistry defined by the (4R,5R) configuration plays a pivotal role in determining its biological activity and reactivity, making it a subject of intense study among researchers.

The< strong> (4R,5R)-5-Methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid molecule belongs to a class of heterocyclic compounds that exhibit remarkable versatility in chemical transformations. The presence of the methoxycarbonyl group and the dimethyl substitution on the dioxolane ring enhances its utility in various synthetic pathways. These structural attributes make it an attractive intermediate in the synthesis of more complex molecules, particularly in the pharmaceutical industry where precise molecular architecture is crucial for achieving desired pharmacological effects.

Recent advancements in medicinal chemistry have highlighted the importance of stereospecific compounds like (4R,5R)-5-Methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid. The stereochemistry at the 4 and 5 positions significantly influences the compound's interaction with biological targets. This has led to increased interest in developing methods for the efficient synthesis and resolution of stereoisomers. The use of chiral auxiliaries and catalysts has been particularly effective in achieving high enantiomeric purity, which is essential for therapeutic applications.

In the context of drug discovery, the< strong> (4R,5R)-5-Methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid compound has been explored as a key intermediate in the synthesis of novel bioactive molecules. Its structural framework allows for modifications that can fine-tune biological activity, making it a valuable building block for lead optimization. Researchers have leveraged its reactivity to develop new therapeutic agents targeting various diseases. The compound's ability to undergo selective functionalization has opened up avenues for designing molecules with enhanced efficacy and reduced side effects.

The< strong> stereochemistry of< strong> (4R,5R)-5-Methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid is particularly noteworthy. The (4R) and (5R) configurations dictate its interaction with enzymes and receptors in biological systems. This stereochemical control is critical for ensuring that the compound exerts its intended therapeutic effect without unintended consequences. Advances in asymmetric synthesis have enabled researchers to produce enantiomerically pure forms of this compound, which are essential for clinical trials and commercial drug development.

The< strong> methoxycarbonyl group present in< strong> (4R,5R)-5-Methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid contributes to its reactivity and functionality. This group can participate in various chemical reactions, including esterification and condensation reactions, which are commonly used in organic synthesis. Its presence also influences the compound's solubility and stability properties, making it suitable for various applications in pharmaceutical formulations.

The< strong> dimethyl substitution on the dioxolane ring adds another layer of complexity to< strong> (4R,5R)-5-Methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid. This substitution not only affects the compound's electronic properties but also influences its interaction with biological targets. The dimethyl groups can act as steric shields or hydrophobic anchors depending on the context of use. This flexibility makes it a versatile building block for designing molecules with tailored properties.

In recent years,< strong> (4R,5R)-5-Methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid has been utilized in several high-profile research projects aimed at developing new treatments for chronic diseases. Its role as a key intermediate has been instrumental in synthesizing novel compounds that exhibit promising biological activity. These studies have underscored the importance of stereochemistry and functional group design in drug development processes.

The< strong> synthetic methodologies employed for producing< strong> (4R,5R)-5-Methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid have seen significant advancements over recent years. New catalytic systems and reaction conditions have been developed to improve yield and enantioselectivity. These innovations have made it possible to produce large quantities of this compound under controlled conditions suitable for industrial-scale applications.

The< strong> potential applications of< strong> (4R,5R)-5-Methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid extend beyond pharmaceuticals into other areas such as agrochemicals and materials science. Its unique structural features make it a valuable candidate for developing new materials with specialized properties. Researchers are exploring its use as a precursor for polymers that exhibit enhanced durability or biodegradability.

In conclusion,< strong>CAS No. 67812-33-> specifically identified as()-(S)-N-(tert-Butoxycarbonyl)-N'-methylcysteine methyl ester hydrochloride CAS NO:67812 - 33 - 3) , represents a significant molecule with diverse applications in chemical synthesis and pharmaceutical research.
The stereochemistry defined by(S)-(S)-N-(tert-Butoxycarbonyl)-N'-methylcysteine methyl ester hydrochloride CAS NO:67812 - 33 - 3) plays a pivotal role.
The methoxycarbonyl group present(S)-(S)-N-(tert-Butoxycarbonyl)-N'-methylcysteine methyl ester hydrochloride CAS NO:67812 - 33 - 3).
The dimethyl substitution on dioxolane ring adds another layer complexity.
Recent advancements highlight importance stereospecific compounds like(S)-(S)-N-(tert-Butoxycarbonyl)-N'-methylcysteine methyl ester hydrochloride CAS NO:67812 - 33 - 3). It’s been explored key intermediate synthesis novel bioactive molecules.
Researchers leverage reactivity develop new therapeutic agents targeting various diseases.
Advances asymmetric synthesis enabled production enantiomerically pure forms.
Methoxycarbonyl group contribute reactivity functionality.
Dimethyl substitution affects electronic properties influences interaction biological targets.
Recent years utilized several high-profile research projects aimed developing new treatments chronic diseases.
Synthetic methodologies employed producing(S)-(S)-N-(tert-Butoxycarbonyl)-N'-methylcysteine methyl ester hydrochloride CAS NO:67812 - 33 - 3) seen significant advancements.
Potential applications extend beyond pharmaceuticals into other areas such as agrochemicals materials science.

• 6947-05-3(1,3-Dioxolane-4,5-dicarboxylicacid, 2-ethyl-2-methyl-, 4,5-dimethyl ester)
• 36183-27-4(1,3-Dioxolane-4-carboxylicacid, 2,2,5-trimethyl-, methyl ester, (4R,5R)-rel-)
• 59779-75-8((4R,5R)-4,5-Diethoxycarbonyl-2,2-dimethyldioxolane)
• 37031-30-4(2,3-O-Isopropylidene-D-tartaric Acid, Dimethyl Ester)
• 78086-72-3(Methyl 4-deoxy-2,3-O-isopropylidene-L-threonate)
• 37031-29-1(dimethyl (4R,5R)-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylate)
• 38410-80-9((4S,5R)-Methyl 2,2,5-trimethyl-1,3-dioxolane-4-carboxylate)
• 67844-13-7(1,3-Dioxolane-4-carboxylic acid, 5-(hydroxymethyl)-2,2-dimethyl-, methyl ester, (4R,5S)-)
• 824985-33-3(INDEX NAME NOT YET ASSIGNED)
• 28762-00-7(1,3-Dioxolane-4-carboxylic acid, 5-(hydroxymethyl)-2,2-dimethyl-, methyl ester, (4S,5R)-)